PrimeRFP SCOUT · Federal Contract Recompete Brief

36C77021N0218Valbenazine 40mg ORAL CAP 30ct NDC — Neurocrine Biosciences, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 30, 2021 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

National Cmop Office (36C770)
Awarding office
Neurocrine Biosciences, Inc
Recipient
Sep 30, 2021
PoP end
$678K
Obligated
$678K
Potential
325412
NAICS
6505
PSC
1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Neurocrine Biosciences, Inc — $90

Contract facts

Federal
Contract number36C77021N0218
Also listed as36C770-21-N-0218
Also listed as36F79718D0414-36C77021N0218
AgencyNational Cmop Office (36C770)
Awarding officeNational Cmop Office (36C770)
Awarding agencyDepartment of Veterans Affairs (VA)
Funding agencyDepartment of Veterans Affairs (VA)
IncumbentNeurocrine Biosciences, Inc
CAGE5H9C3
UEIGMQSH4CZ7EC9
NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505
Parent IDIQ / IDV36F79718D0414
Place of performanceSAN DIEGO CA
Pricing typeFirm Fixed Price
Extent competedFull And Open Competition
PoP startSep 8, 2021
PoP end (current)Sep 30, 2021
Obligated$678K
Current value$678K
Potential value$678K

VALBENAZINE 40MG ORAL CAP 30CT NDC: 70370-2040-01 VALBENAZINE 80MG ORAL CAP 30CT NDC: 70370-1080-01) is a federal award for National Cmop Office (36C770) held by Neurocrine Biosciences, Inc. Estimated value $678K ($678K obligated). Current period of performance ends Sep 30, 2021. Last award drew 1 bidder. Place of performance: SAN DIEGO CA.

VALBENAZINE 40MG ORAL CAP 30CT NDC: 70370-2040-01 VALBENAZINE 80MG ORAL CAP 30CT NDC: 70370-1080-01)

Recompete timing

Public
Past PoP end (1786 days ago)

Current PoP ended Sep 30, 2021 (1786 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Explore more pipelines →

Frequently asked questions

What is contract 36C77021N0218?

36C77021N0218 (Valbenazine 40mg ORAL CAP 30ct NDC) is a National Cmop Office (36C770) award with a potential value of $678K, currently held by Neurocrine Biosciences, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C770-21-N-0218?

36C770-21-N-0218 is the dashed form of PIID 36C77021N0218 (Valbenazine 40mg ORAL CAP 30ct NDC), held by Neurocrine Biosciences, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C77021N0218?

National Cmop Office (36C770) awarded 36C77021N0218 to Neurocrine Biosciences, Inc (potential $678K).

Who is the incumbent on 36C77021N0218?

Neurocrine Biosciences, Inc is the incumbent. The current period of performance ends Sep 30, 2021.

When does Neurocrine Biosciences, Inc’s 36C77021N0218 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2021. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthly
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/36C77021N0218